Compare OSPN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSPN | ENTA |
|---|---|---|
| Founded | 1991 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 449.1M | 486.3M |
| IPO Year | 1998 | 2013 |
| Metric | OSPN | ENTA |
|---|---|---|
| Price | $11.15 | $13.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $17.00 | ★ $20.40 |
| AVG Volume (30 Days) | ★ 476.8K | 221.4K |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ 99.92 | N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $241,436,000.00 | $65,324,000.00 |
| Revenue This Year | $0.69 | $0.99 |
| Revenue Next Year | $1.96 | $0.19 |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.00 | $4.09 |
| 52 Week High | $20.37 | $17.15 |
| Indicator | OSPN | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.97 | 50.82 |
| Support Level | $11.26 | $12.45 |
| Resistance Level | $12.21 | $13.66 |
| Average True Range (ATR) | 0.52 | 0.56 |
| MACD | -0.08 | 0.09 |
| Stochastic Oscillator | 38.16 | 75.75 |
OneSpan Inc is a provider of information technology security solutions for banking and financial services and application security markets. Its solutions secure and manage access to digital assets and protect online transactions, via mobile devices and in-person. Authentication and anti-fraud solutions are the organization's primary product offerings and include multifactor authentication and virtual private network access capabilities. The company derives revenues from hardware and license fees, maintenance and support fees, and subscription fees. A large majority of the firm's revenue is generated in Europe, the Middle East, and Africa, and the rest in the United States and Asia-Pacific region.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.